Teva And Endo Settle Opioid Claims In Louisiana With Millions In Cash

Israeli Giant ‘Is Continuing To Negotiate A National Settlement’

Teva underlined that it was open to further individual state settlements in its broad and sweeping opioid litigation after reaching a deal with the Louisiana Attorney General's office.

claims
Teva And Endo Have Both Reached Proposed Deals • Source: Alamy

Teva Pharmaceutical Industries Ltd. is continuing to negotiate a national settlement and remains “open in parallel to pursuing opportunities with individual states” after reaching an agreement in principle with the Louisiana attorney general’s office to settle claims it fueled the opioid crisis in the US.

The Israeli giant’s agreement was announced as fellow defendant Endo International plc also reached a deal to settle all...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin